靶向CD36调控脂质代谢:糖尿病心肌病防治新靶点  

Targeting CD36 to regulate lipid metabolism:a new strategy for the prevention and treatment of diabetic cardiomyopathy

作　　者：周嘉琪 林介夫 陈嘉佳 谢林 夏正远 ZHOU Jiaqi;LIN Jiefu;CHEN Jiajia;XIE Lin;XIA Zhengyuan(Department of Anesthesiology,Affiliated Hospital of Guangdong Medical University,Zhanjian,Guangdong 524000,China;State Key Laboratory of Pharmaceutical Biotechnology,Department of Medicine,University of Hong Kong,Hong Kong 999077,China;Doctoral Training Platform for Research and Translation,Boshiwan,Guanchong Village,Zhongxiang,Hubei 431900,China)

机构地区：[1]广东医科大学附属医院麻醉科,广东省湛江市524000 [2]香港大学生物医药技术国家重点实验室,中国香港999077 [3]湖北省钟祥市官冲博士塆科研与转化培训平台,湖北省钟祥市431900

出　　处：《中国动脉硬化杂志》2023年第12期1013-1019,共7页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金项目(82270306)。

摘　　要：脂质代谢异常诱发心肌结构和功能紊乱,进而导致糖尿病心肌病(DCM)的形成,已成为当前DCM研究的热点。CD36是主要的脂质跨膜转运蛋白,参与调节心脏脂质代谢,在DCM导致心肌损伤的分子机制中具有关键作用。本文总结了CD36的结构及其在特定细胞类型中的作用,并进一步探讨CD36在DCM中的病理生理作用,以及CD36作为靶点的潜在药物治疗策略。Abnormalities in lipid metabolism induce myocardial structural and functional disorders,leading to the development of diabetic cardiomyopathy(DCM),which has become a hotspot in current DCM research.The transmembrane glycoprotein CD36 is a multifunctional membrane protein that facilitates fatty acid transport,which is involved in the regulation of cardiac lipid metabolism.CD36 signaling plays a key role in the pathogenesis of DCM mediated cardiac injuries.This article summarizes the structure of CD36 and its role in specific cell types,and further explores the pathophysiological role of CD36 in DCM,proposing that targeting CD36 may prove to be a potential pharmacological strategy in the prevention and treatment of DCM.

关 键 词：CD36 糖尿病心肌病 脂质代谢 心肌缺血再灌注损伤 

分 类 号：R5[医药卫生—内科学] R363[医药卫生—临床医学]